<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TERIPARATIDE</span><br/>(ter-i-par'a-tide)<br/><span class="topboxtradename">Forteo<br/></span><b>Classifications:</b> <span class="classification">hormones &amp; synthetic substitutes</span>; <span class="classification">parathyroid hormone agonist</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>750 mcg/3 mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Parathyroid hormone (PTH) is the primary regulator of calcium and phosphate metabolism in bone and kidney. Actions of PTH
         include regulation of bone metabolism, renal reabsorption of calcium and phosphate, and intestinal calcium absorption. The
         biological actions of PTH and teriparatide are similar in bone and the kidneys.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Stimulates new bone formation by preferential stimulation of osteoblastic activity over osteoclastic activity; improves bone
         microarchitecture, and increases bone mass and strength by stimulating new bone formation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of osteoporosis in postmenopausal women at high risk for fracture; increase bone mass in men with primary or hypogonadal
         osteoporosis who are at high risk for fracture.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to teriparatide; osteosarcoma; Paget's disease; unexplained elevations of alkaline phosphatase; bone metastases
         or a history of skeletal malignancies; metabolic bone diseases other than osteoporosis; preexisting hypercalcemia; prior history
         of radiation therapy involving the skeleton; pediatric patients or young adults with open epiphyses; children; lactation;
         pregnancy (category C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Active or recent urolithiasis, hypercalciuria; hypotension; concurrent use of digitalis; hepatic, renal, and cardiac disease.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Osteoporosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 20 mcg q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Do not administer to anyone with hypercalcemia. Consult physician.</li>
<li>Rotate SC injection sites.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Pain,</span> asthenia, neck pain. <span class="typehead">CNS:</span> Headache, dizziness, depression, insomnia, vertigo. <span class="typehead">CV:</span> Hypertension, angina, syncope. <span class="typehead">GI:</span> Nausea, constipation, dyspepsia, vomiting. <span class="typehead">Metabolic:</span> <span class="speceff-common">Transient increase in calcium levels,</span> increase in serum uric acid, antibodies to teriparatide after 12 mo therapy. <span class="typehead">Musculoskeletal:</span> <span class="speceff-common">Arthralgia,</span> leg cramps. <span class="typehead">Respiratory:</span> Rhinitis, cough, pharyngitis, dyspnea, pneumonia. <span class="typehead">Skin:</span> Rash, sweating. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase risk of <b>digoxin</b> toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Extensively absorbed from SC site. <span class="typehead">Onset:</span> 2 h for calcium concentration increase. <span class="typehead">Peak:</span> Max. calcium concentrations 46 h. <span class="typehead">Duration:</span> 1624 h. <span class="typehead">Metabolism:</span> Parathyroid hormone is metabolized non-specific enzymes. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 1 h SC. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cardiovascular status including BP and subjective reports of angina.</li>
<li>Lab tests: Monitor periodically serum calcium, alkaline phosphatase, uric acid and bone density levels.</li>
<li>Concurrent drugs: Monitor closely for digoxin toxicity with concurrent use.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report unexplained leg cramps and bone pain.</li>
<li>Learn correct technique for SC injection.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>